v3.26.3
SUMMARY OF OUTSTANDING WARRANTS (Details) - USD ($)
$ / shares in Units, $ in Thousands
 6 Months Ended
Sep. 30, 2026
Aug. 31, 2026
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Number of Warrants 5,174,059  
Exercise Price $ 10.66 $ 0.01
Intrinsic Value $ 3,348  
NitricGen Agreement [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Number of Warrants 200  
Exercise Price $ 2,760.00  
Intrinsic Value  
Date of Expiration January 2028  
Avenue Agreement [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Number of Warrants 585  
Exercise Price $ 151.72  
Intrinsic Value  
Date of Expiration June 2028  
March 2024 Raise [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Number of Warrants 24,108  
Exercise Price $ 900.00  
Intrinsic Value  
Date of Expiration March 2027  
Avenue Extension Agreement [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Number of Warrants 250  
Exercise Price $ 512.00  
Intrinsic Value  
Date of Expiration June 2029  
September 2024 equity offering [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Number of Warrants 27,764  
Exercise Price $ 151.72  
Intrinsic Value  
Date of Expiration September 2029  
September 2024 Debt Instrument [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Number of Warrants 63,542  
Exercise Price $ 39.00  
Intrinsic Value  
Date of Expiration September 2029 / November 2030  
September 2025 Inducement [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Number of Warrants 35,982  
Exercise Price $ 44.20  
Intrinsic Value  
Date of Expiration September 2030  
January, 2026 Equity Offering [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Number of Warrants 196,542  
Exercise Price $ 22.94  
Intrinsic Value  
Date of Expiration January 2031  
July 2026 equity offering (Series A) [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Number of Warrants 1,805,846  
Exercise Price $ 5.51  
Intrinsic Value  
Date of Expiration [1] July 2027  
July 2026 equity offering (Series B) [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Number of Warrants 1,805,846  
Exercise Price $ 5.51  
Intrinsic Value  
Date of Expiration July 2031  
Sub Total [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Number of Warrants 3,960,665  
Exercise Price $ 13.93  
Intrinsic Value  
Pre-funded warrants (Sep-2024 offering) [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Number of Warrants 11,002  
Exercise Price $ 0.040  
Intrinsic Value $ 30  
Date of Expiration September 2029  
Pre-funded warrants (Jul-2026 offering) [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Number of Warrants 1,202,392  
Exercise Price $ 0.0001  
Intrinsic Value $ 3,318  
Date of Expiration N/A  
[1] The July 2026 equity offering (Series A) warrants will expire on the earlier of (i) the first anniversary of their issuance or (ii) the date that is 45 days following approval by the U.S. Food and Drug Administration of the Company’s pending premarket approval supplement for LungFit® PH II.